Hydroxybutyl Beta Cyclodextrin
Quick Details
|
Name |
Hydroxybutyl beta cyclodextrin |
|
Synonym |
Hydroxybutyl-β-cyclodextrin; Hydroxybutyl-beta-Cyclodextrin; |
|
Molecular Formula |
C42H70O35 (C4H8O)n |
|
Abbreviation |
HPBCD |
|
Appearance/Odor |
White powder, odorless |
|
Package |
10kg/drum |
|
Application |
Pharmaceutical/Food/Cosmetics/Industrial/Scientific Research Reagents |
|
Storage |
Store at room temperature and sealed. |
Advantages
Hydroxybutylbeta Cyclodextrin is a new patent protected Cyclodextrin derivative. The unique modification group of hydroxybutylbeta Cyclodextrin makes it have good water solubility of hydroxypropyl Cyclodextrin and larger hydrophobic inclusion cavity of methylated Cyclodextrin.
Function
1
In the pharmaceutical field:
Hydroxybutylbeta Cyclodextrin can improve the solubility and bioavailability of drugs, increase the efficacy of drugs or reduce the dosage, adjust or control the release rate of drugs, reduce the toxic and side effects of drugs, and enhance the stability of drugs.
2
In the field of food and spices:
Hydroxybutylbeta Cyclodextrin can improve the stability and long-term effect of nutrition molecules, and can cover up or correct the bad smell and taste of food nutrition molecules.
3
In the field of cosmetics:
Hydroxybutylbeta Cyclodextrin can reduce the irritation of organic molecules in cosmetics to skin and mucosa, enhance the stability of substances, and prevent the volatilization and oxidation of nutrients.
4
The guest molecule shows excellent performance in Chiral resolution.
Practical Application
Tacrolimus, also known as FK506, was first isolated from Streptomyces tsukubaensis by the Fujisawa Pharmaceutical Industrial Research Institute in Japan in 1984. Its chemical structure is a 23-membered macrocyclic lactone antibiotic. It is a potent new immunosuppressant that primarily works by inhibiting the release of interleukin-2, effectively suppressing the action of T lymphocytes, being 100 times more potent than cyclosporine.
On June 7, 1993, tacrolimus was first approved for marketing in Japan, followed by several dozen countries including the UK, the US, and Germany. It is used for acute anti-rejection therapy in liver, kidney, and bone marrow transplants. Formulations developed include capsules, injections, and ointments. Due to the crystalline structure of raw tacrolimus materials, the preparation of a solid dispersion is aimed at rendering it amorphous. Current technology is limited to preparing solid dispersions of tacrolimus, but if formulated to an amorphous form using formulation technology, the same effect can be achieved, with no aging issues associated with solid dispersions. Dissolving tacrolimus in ethanol and using this solution as a binder to granulate excipients results in rapidly dissolving tacrolimus capsules, although the viscosity of tacrolimus ethanol solution is low, leading to poor flowability of the granules and significant differences in dosing volume.
The inventors jointly employed cyclodextrin complexation technology, adding hydroxypropyl β-cyclodextrin, to prepare an amorphous tacrolimus complex through simple granulation and drying, dissolving hydroxypropyl β-cyclodextrin in ethanol with a certain viscosity for use as a binder, resulting in granules with good flowability.
Hot Tags: hydroxybutyl beta cyclodextrin, China hydroxybutyl beta cyclodextrin manufacturers, suppliers, desirable product, visually appealing product, limited edition product, Chlorpropanol Cyclodextrin, gift product, newly launched product
You Might Also Like
Send Inquiry